Xenon Pharmaceuticals Inc
XENE
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.32B
Close$
$2.34
95.6% downside
Current Fair Value
95.6% downsideOvervalued by 95.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.32 Billion |
|---|---|
| Enterprise Value | $3.78 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.36 |
| Beta | 0.65 |
| Outstanding Shares | 87,345,717 |
Return
| Return on Equity | -27.63% |
|---|---|
| Return on Assets | -27.63% |
| Return on Invested Capital | -30.26% |
Valuation & Multiples
| P/E Ratio | -12.48 |
|---|---|
| PEG | -21.78 |
| Price to Sales | - |
| Price to Book Ratio | 3.56 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.28 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-1.17
Average shareholder expectationRevenue Estimate
$1.36 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-1.16
Average shareholder expectationRevenue Estimate
$1.36 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1556▼ 76.22% |
|---|---|
| Total Calls | 1,844,200▲ 205.89% |
| Total Puts | 2,131,100▲ 84.32% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 126.46%▲ 19.89% |
|---|---|
| Total Invested | $5.80B▲ 53.37% |
| Investors Holding | 305▲ 44.00% |
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone